Alector, Inc. (ALEC)

NMS – Real vaqt narxi. Valyuta: USD

2.16

+0.11 (5.37%)

Yopilishda: May 12, 2026, 4:00 PM EDT

08.05.2026

Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates

Alector (ALEC) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.41 per share a year ago.

07.05.2026

Alector Reports First Quarter 2026 Financial Results and Provides Business Update

Advancing the Alector Brain Carrier (ABC) platform across multiple therapeutic modalities, including antibodies, enzymes, and siRNA, with continued progress across AL037/AL137 (ABC-enabled antibody for Alzheimer's disease (AD)), AL050 (ABC-enabled GCase Enzyme Replacement Therapy for Parkinson's disease (PD)), and AL064/AL164 (ABC-enabled Tau siRNA for AD and other tauopathies)

07.05.2026

Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

29.04.2026

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis

--Independent data monitoring committee (IDMC) determined the trial unlikely to meet primary endpoint – --Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including an anti-Aβ antibody for Alzheimer's disease (AD), a GCase enzyme replacement therapy (ERT) for Parkinson's disease (PD), a tau siRNA for AD, an α-synuclein siRNA for PD, and an NLRP3 siRNA for multiple neurological and metabolic disorders, alongside several first-in-class discovery programs— SOUTH SAN FRANCISCO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today confirmed that the Phase 2 PROGRESS-AD trial of nivisnebart (AL101/GSK4527226) in individuals with early Alzheimer's disease (AD) will be discontinued.

10.03.2026

Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross

After reaching an important support level, Alector, Inc. (ALEC) could be a good stock pick from a technical perspective. ALEC recently experienced a "golden cross" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.

10.03.2026

Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles

Three health-technology names are drawing fresh analyst attention this week as strategic partnerships and business pivots reframe the risk-reward calculus for each.

06.03.2026

Alector, Inc. (ALEC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Alector, Inc. (ALEC)

Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates

Alector Reports First Quarter 2026 Financial Results and Provides Business Update

Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis

Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross

Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles

Alector, Inc. (ALEC) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates

Alector Reports First Quarter 2026 Financial Results and Provides Business Update

Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis

Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross

Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles

Alector, Inc. (ALEC) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Videolar

No Data

Press-relizlar

Alector Reports First Quarter 2026 Financial Results and Provides Business Update

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis

Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Alector to Participate in the TD Cowen 46th Annual Health Care Conference

Search stocks

Alector, Inc. (ALEC)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz bilan bog'lanish

Bizni kuzating

Alector, Inc. (ALEC)

Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates

Alector Reports First Quarter 2026 Financial Results and Provides Business Update

Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis

Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross

Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles

Alector, Inc. (ALEC) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Alector (ALEC) Reports Q1 Loss, Lags Revenue Estimates

Alector Reports First Quarter 2026 Financial Results and Provides Business Update

Will Alector (ALEC) Report Negative Q1 Earnings? What You Should Know

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis

Alector (ALEC)'s Technical Outlook is Bright After Key Golden Cross

Wall Street Turns Bullish on HIMS, TDOC and ALEC as Partnerships Reshape Risk Profiles

Alector, Inc. (ALEC) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Videolar

No Data

Press-relizlar

Alector Reports First Quarter 2026 Financial Results and Provides Business Update

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis

Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Alector to Participate in the TD Cowen 46th Annual Health Care Conference